Quantcast

Latest XDX Inc. Stories

2010-04-22 08:55:00

CHICAGO, April 22 /PRNewswire/ -- The International Society for Heart & Lung Transplantation (ISHLT) and XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced results from the Invasive Monitoring Attenuation through Gene Expression (IMAGE) clinical trial. The IMAGE results were presented during a plenary session at the ISHLT 30th Anniversary Meeting & Scientific Sessions in Chicago...

2010-04-16 07:30:00

BRISBANE, Calif., April 16 /PRNewswire/ -- XDx, Inc., a molecular diagnostics company focused on noninvasive tests for the monitoring of immune-mediated conditions, today announced that results from its Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial will be presented by Dr. Michael X. Pham, Stanford University Medical Center, during a plenary session at the International Society for Heart & Lung Transplantation 30th Anniversary Meeting & Scientific Sessions...

09f519a185cc9e6c44bd150cbfce5fe01
2008-08-28 13:00:00

On Wednesday, government regulators cleared the way for broader use of a blood test that can spare heart transplant patients the ordeal of repeated biopsies to check if their bodies are rejecting the new organ. The test, called AlloMap, is an example of how the science of genetics is changing the practice of medicine, the Food and Drug Administration said. Certain kinds of genetic information contained in white blood cells are analyzed in the test, including cells that help the body fight off...

2008-08-27 06:00:20

XDx, Inc. has received market clearance from the U.S. Food and Drug Administration (FDA) for AlloMap(R) Molecular Expression Testing. The AlloMap Test is a noninvasive, multi-gene molecular diagnostics blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing, in conjunction with standard clinical assessment. XDx is the first U.S. molecular diagnostics...

2008-07-23 09:01:21

The Personalized Medicine Coalition (PMC) today announced the appointment of Pierre G. Cassigneul, president and chief executive officer of XDx, Inc., and David P. King, chief executive officer, president and director of Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), to its Board of Directors. The PMC, an educational and advocacy group dedicated to advancing the understanding and adoption of personalized medicine, was launched in 2004 by more than 15 leading...

2004-12-01 09:00:11

Sprout Group announced today that it has led a $20 million Series D private equity financing in XDx, Inc., a molecular diagnostics company. Sprout Group invested $7 million in the financing, with the remainder coming from new investors JP Morgan's Bay Area Equity Fund, Integral Capital Partners and Burrill & Company, as well as existing investors Kleiner Perkins Caufield & Byers and TPG Ventures. In connection with the financing, Vijay Lathi, a partner at Sprout Group investing in...

2004-12-01 09:00:11

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire/ -- XDx, Inc., a molecular diagnostics company, announced today that it has completed a $20 million Series D private equity financing. Sprout Group led the investment, with additional participation from new investors JP Morgan's Bay Area Equity Fund, Integral Capital Partners and Burrill & Company, as well as existing investors Kleiner Perkins Caufield & Byers and TPG Ventures. With the proceeds of the financing, XDx will launch...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related